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Background: A number of reports have been published 
regarding the use of imiquimod for the treatment of me-
lanoma in situ and metastatic melanoma. Essential steps in 
the process of melanoma invasion and metastasis include 
degradation of basement membranes and remodeling of the 
extracellular matrix by proteolytic enzymes, including 
matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs). Objective: To evaluate the anti- 
invasive effect of imiquimod in human malignant melanoma 
cell lines, SK-MEL-2 and SK-MEL-24, in vitro, and to inve-
stigate imiquimod-induced changes in the expression of 
MMPs and TIMPs. Methods: Invasiveness of melanoma cell 
lines following imiquimod treatment was evaluated by 
invasion assays. In order to investigate the mechanism of the 
anti-invasive effect of imiquimod, mRNA and protein levels 
of MMP-2, -9, membrane type 1 (MT1)-MMP, TIMP-1, and -2 
were assessed by real-time reverse transcription-polymerase 
chain reaction, gelatin zymography, and western blotting. 
Results: Imiquimod treatment decreased in vitro viability of 
melanoma cells in a concentration-dependent manner. Imi-
quimod also elicited a concentration-dependent suppress-
ion of invasion in both melanoma cell lines. A concen-
tration-dependent decrease in MMP-2 and MT1-MMP 
protein levels and a concentration-dependent increase in 
TIMP-1 and -2 protein levels by imiquimod was observed in 
both melanoma cell lines. However, expression of MMP-9 
protein was increased in SK-MEL-2 but decreased in 
SK-MEL-24 with increasing imiquimod concentrations. 
Imiquimod elicited alterations in MMPs and TIMPs mRNA 
levels that parallel the observed changes in protein levels. 
Conclusion: Imiquimod may elicit an anti-invasive effect on 
human melanoma cells by regulating MMPs and TIMPs.  
(Ann Dermatol 26(3) 363∼373, 2014)
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INTRODUCTION
Imiquimod is an immune response modulator, which is 
used for the treatment of actinic keratoses, superficial 
basal cell carcinomas, and genital and perianal warts. 
Imiquimod has also been used in the treatment of me-
lanoma in situ and metastatic melanoma in patients with 
confounding morbidities who are not considered candi-
dates for surgery, with extensive disease or disease in 
areas that are not amenable to surgery1-5.
Melanoma is a well-known tumor that tends to meta-
stasize, rather than grow locally. During the process of 
tumor invasion, essential steps include the degradation of 
basement membranes and remodeling of the extracellular 
matrix (ECM) by proteolytic enzymes such as matrix meta-
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lloproteinases (MMPs) under regulation by tissue inhi-
bitors of metalloproteinases (TIMPs). MMPs, particularly 
MMP-2 and MMP-9, are key enzymes known to degrade 
the components of surrounding ECM during cancer inva-
sion and metastasis. Melanoma cells express a number of 
MMPs and TIMPs6.
So far, there has only been one case report investigating 
the changes in the expression of factors involved in mela-
noma metastasis after treatment with imiquimod7. In that 
study, a skin metastatic lesion was biopsied before and 
after treatment with imiquimod, and the expression of the 
molecular regulators investigated using real-time reverse 
transcription-polymerase chain reaction (RT-PCR). Follow-
ing imiquimod treatment, the expression of TIMP-1, 
KiSS-1, and MMP-1 was up-regulated, that of MMP-2 was 
not altered, and MMP-9 expression was dramatically de-
creased. These findings suggest that imiquimod could 
repress metastasis and inhibit melanoma invasion7.
The aim of the current study was to evaluate the anti- 
invasive effects of imiquimod in vitro against human mali-
gnant melanoma cell lines. Additionally, this study also 
investigated imiquimod-induced changes in the expre-
ssion of key ECM-degrading enzymes MMP-2, -9, and 
membrane type 1 MMP (MT1-MMP), along with their in-
hibitors TIMP-1 and -2. The targets of this investigation are 
key enzymes known to degrade the surrounding ECM 
components during cancer invasion and metastasis.
MATERIALS AND METHODS
Cell culture
Melanoma cell lines, SK-MEL-2 and SK-MEL-24, as well as 
the HT1080 cell line (used as a positive control), were 
obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA) and maintained using routine 
procedures. SK-MEL-2 and SK-MEL-24 were maintained in 
Eagle’s minimal essential medium (Lonza, Basel, Swit-
zerland) containing 10% fetal bovine serum (FBS; Lonza) 
and supplemented with 100 units/ml penicillin and 100 
mg/ml streptomycin. HT1080 cells were maintained in 
RPMI-1640 (Lonza) containing 10% FBS and supplemen-
ted with 100 units/ml penicillin and 100 mg/ml strep-
tomycin.
Cell viability assay
SK-MEL-2 and SK-MEL-24 cells were harvested in the 
exponential growth phase and seeded in a 96-well flat- 
bottom tissue culture plate at a concentration of 1×104 
cells/100 μl in each well. Cells were allowed to grow 
and stabilize for 24 hours. Subsequently, the cells were 
treated with a range of concentrations (5∼200 μg/ml) of 
imiquimod (InvivoGen, San Diego, CA, USA) prepared in 
a complete medium or cultured for a range of incubation 
times (6 hours∼3 days). Each treatment was performed in 
three replicates wells. After incubation, 10 μl of WST-1 
reagent EZ-CyTox (Daeil Lab, Seoul, Korea) was added to 
each well, followed by incubation for 4 hours at 37oC. 
Optical density was measured using enzyme-linked immu-
nosorbent assay plate reader (Molecular Devices; Spectra 
Max 190 with Soft max Pro, Sunnyvale, CA, USA) at 450 
nm with a reference wavelength of 690 nm. Cell viability 
was plotted as a percentage of untreated control. Results 
are expressed as mean±standard error of the mean and 
are representative of three independent experiments. The 
half maximal inhibitory concentration (IC50) was determi-
ned from the dose-effect curve as the drug concentration 
that decreased cell viability to 50% of the original value.
Invasion assay using transwell filters
A modified version of the standard transwell filter assay 
commonly used for evaluating invasion was performed. 
Transwell filters (diameter, 6.5 mm; pore size, 8 μm; 
Falcon, Becton Dickinson and Company, Franklin Lakes, 
NJ, USA) were coated on the lower side with 8 μg/μl 
matrigel and placed on a 24-well plate containing me-
dium supplemented with 0.1% bovine serum albumin 
(BSA; USB, Cleveland, OH, USA). SK-MEL-2 and SK- 
MEL-24 were harvested with a cell dissociation solution 
(Sigma-Aldrich, St Louis, MO, USA) and suspended in 
medium with 1% BSA. Cancer cells (1×105 cells) were 
added to the upper compartment of a transwell chamber 
and treated with 0, 10, and 30 μg/ml imiquimod added 
to the upper compartment for 24 hours at 37oC. After 24 
hours, non-migrated cells on the upper side of the mem-
brane were removed with a cotton swab, and migrated 
cells on the bottom surface of the membrane were fixed in 
3.7% paraformaldehyde in phosphate buffered saline 
(Lonza) and stained with crystal violet for 10 minutes at 
room temperature. Cell migration was quantified by 
counting the number of cells in three inserts. Data were 
expressed as the average number of cells per insert.
Gelatin zymography
SK-MEL-2, SK-MEL-24, and HT1080 cell lines were cul-
tured in serum-free media for 24 hours, and the con-
ditioned media was concentrated using VIVASPIN 20 
(Sartorius Stedim Biotech GmbH, Goettingen, Germany). 
An equal volume of sample buffer was added to the con-
centrated media before loading on a 10% sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
gel impregnated with 0.1% gelatin. After electrophoresis, 
the gel was rinsed with renaturing buffer for 1 hour and 
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incubated in a developing buffer overnight at 37oC. After 
incubation, the gel was stained with 0.05% Coomassie 
brilliant blue R-250 (Amresco, Cleveland, OH, USA) and 
de-stained. MMP-2 and MMP-9 were detected as 
transparent bands. The HT1080 cell line was used as a 
positive control.
Western blot analysis
To evaluate the expression of MT1-MMP, whole-cell pro-
tein extracts were prepared from SK-MEL-2, SK-MEL-24, 
and HT1080 cells treated with a range of concentrations 
of imiquimod (0, 5, 10, and 30 μg/ml) for 24 hours. 
Protein content was determined by the bicinchoninic acid 
(BCA) assay method. Aliquots of each sample (40 μg of 
total protein per sample) were fractionated by 10% 
SDS-PAGE gel and transferred onto nitrocellulose 
membranes (GE Healthcare, Little Chalfont, UK). After 
blocking with 5% skimmed milk, the membranes were 
incubated with polyclonal antibody against MT1-MMP (1 : 
500 dilution; Abcam Inc., Cambridge, UK) and 
monoclonal antibody against actin (1 : 4,000 dilution; 
Santa Cruz biotechnology, Santa Cruz, CA, USA) at 4oC 
overnight. After washing with tris-buffered saline with 
Tween 20 (TBST), the membranes were incubated with 
peroxidase-conjugated goat anti-rabbit immunoglobulin G 
(IgG) antibody (1 : 2,000 dilution; Cell Signaling, Beverly, 
MA, USA) and goat anti-mouse IgG antibody (1 : 2,000 
dilution; Cell Signaling).
To evaluate the expression of TIMP-1 and -2, cell culture 
supernatants were collected from melanoma cell lines and 
HT1080 cell line. Samples of conditioned medium (7 ml) 
were precipitated with 10% trichloroacetic acid (TCA) at 
−20oC overnight. Following centrifugation at 4,300 rpm 
for 20 minutes at 4oC, the pellet was washed twice with 
ice-cold acetone, dried at 37oC, and dissolved in 100 μl 
of 2× SDS sample buffer. An aliquot of each sample (20 
μl per sample) was fractionated by 10% SDS-PAGE gel 
and transferred onto nitrocellulose membranes (GE Hea-
lthcare). After blocking with 5% skimmed milk, mem-
branes were incubated with monoclonal antibodies aga-
inst TIMP-1 (1 : 500 dilution; Abcam Inc.) and TIMP-2 (1 : 
500 dilution; Abcam Inc.) at 4oC overnight. After washing 
with TBST, membranes were incubated with peroxidase- 
conjugated goat anti-mouse IgG antibody (1 : 2,000 
dilution; Cell Signaling). Chemiluminescence reagents 
(ECL Plus Western Blotting Detection Reagents; GE Hea-
lthcare) were used for the visualization of the labeled 
protein bands. The HT1080 cell line was used as a 
positive control. 
Real-time quantitative polymerase chain reaction 
SK-MEL-2, SK-MEL-24, and HT1080 cell lines were treated 
with a range of concentrations of imiquimod (0, 5, 10, and 
30 μg/ml) for 24 hours. Total cellular RNA was purified 
from cancer cells using Trizol® reagent (Gibco BRL; Life Te-
chnologies, Carlsbad, CA, USA). After evaluation by gel ele-
ctrophoresis, the RNA of each sample was stored at −80oC 
until use. The total RNA was converted to single- stranded 
cDNA using a High Capacity kit (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturer’s 
instructions. The resulting cDNA was stored at −20oC. 
Measurements of mRNA levels were based on SYBR® 
Green PCR Master Mix (Applied Biosystems) using the 
7500 Real-Time PCR System (Applied Biosystems). Pri-
mers were designed using Primer Express® Software v3.0 
(Applied Biosystems). Sense and antisense primers for 
MMP-2 were 5’-GCAGACATCGTCATCCAGTTTG-3’ and 
5’-CCGTCCTTCCCGTCGAA-3’, respectively. Sense and 
antisense primers for MMP-9 were 5’-GATGACGATG-
AGCTATGGACCTT-3’ and 5’-TCGGCGTTCCCATACTTC-
AC-3’, respectively. Other primers and probes were syn-
thesized by Assay-on-Demand products (Applied Bio-
systems): MT1-MMP (HS 00237119), TIMP-1 (HS 0017-
1557), TIMP-2 (HS 00234278), and GAPDH (HS 999-
99905). RT-PCR was performed in triplicate 20 μl 
reaction volumes consisting of 10 μl 2× TaqManⓇ Gene 
Expression Master Mix (Applied Biosystems), 1 μl 20× 
Gene Expression Assay Mix, and 9 μl cDNA sample 
diluted in RNase-free water. Two-step PCR cycling was 
carried out as follows: 50oC for 2 minutes and 95oC for 10 
minutes (1 cycle), 95oC for 15 seconds, and 60oC for 1 
minute (50 cycles). Relative expression of mRNA was 
calculated using a relative quantification method, which 
determines the relative expression of a target gene in 
comparison with a reference gene.
Statistical analysis
PASW Statistics 18.0 software (IBM Co., Armonk, NY, 
USA) was used for data analysis. Statistical analysis was 
performed using the Kruskal-Wallis test, followed by the 
Wilcoxon signed-rank test. Differences were regarded as 
significant when the p-values were ＜0.05.
RESULTS
In vitro cell viability
A cell viability assay was performed. Melanoma SK-MEL-2 
and SK-MEL-24 cells were treated with imiquimod and a 
concentration- and incubation time-dependent inhibition 
of cell viability was observed. Fig. 1A shows the con-
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Fig. 1. In vitro cell viability of melanoma cell lines SK-MEL-2 (A) and SK-MEL-24 cells (B) following incubation with a range of 
concentrations of imiquimod. The graphical representation of the dose-effect relationship depicts a concentration-dependent inhibition 
in the percent viability of cells following imiquimod treatment (IC50 values: 56.32 μg/ml for SK-MEL-2, 62.36 μg/ml for SK-MEL-24).
Fig. 2. Invasion assay performed in SK-MEL-2 and SK-MEL-24 cell lines following imiquimod treatment. Suppression of SK-MEL-2 
cell migration and invasion following incubation with a range of concentrations of imiquimod (A) 0 μg/ml, (B) 10 μg/ml, and (C) 
30 μg/ml imiquimod (A∼C: Coomassie stain, ×200). (D) The percentage of invasive SK-MLE-2 melanoma cells was significantly 
decreased with increasing concentrations of imiquimod (*p＜0.05). Suppression of SK-MEL-24 cell migration and invasion following 
treatment with a range of concentrations of imiquimod (E) 0 μg/ml, (F) 10 μg/ml, and (G) 30 μg/ml imiquimod (E∼G: Coomassie 
stain, ×200). (H) The percentage of invasive SK-MLE-24 melanoma cells was significantly decreased with increasing concentrations 
of imiquimod (*p＜0.05). Con A: concanavalin A.
centration-dependent decrease in viability of SK-MEL-2 ce-
lls over 24 hours of incubation. The IC50 value calculated 
from the dose-effect curve was found to be 56.32 μg/ml. 
The viability of SK-MEL-24 cells also decreased with 
increasing imiquimod concentrations over 24 hours of 
incubation (Fig. 1B). The IC50 value of SK-MEL-24 cells 
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Fig. 3. Expression of matrix metalloproteinase (MMP)-2 and -9 protein and mRNA in SK-MEL-2 and SK-MEL-24 cell lines following 
incubation with imiquimod. Expression of MMP-2 decreased with increasing concentrations of imiquimod in SK-MEL-2 cells (A) and 
SK-MEL-24 cells (B). (C) MMP-9 expression in SK-MEL-2 cells was increased by imiquimod treatment in a dose-dependent manner. 
(D) However, expression of MMP-9 was dose-dependently decreased in SK-MEL-24 cells treated with imiquimod. Conditioned media 
of the HT1080 cell line was used as a positive control. Relative mRNA expression of MMP-2 in SK-MEL-2 (E) and SK-MLE-24 (F) 
cells and MMP-9 in SK-MEL-2 (G) and SK-MLE-24 (H) cells, following incubation with a range of concentrations of imiquimod (5, 
10, and 30 μg/ml), compared to controls (0 μg/ml). *p＜0.05 vs. control.
calculated from the dose-effect curve was 62.36 μg/ml.
Imiquimod suppressed the invasion of human mela-
noma cells
To evaluate the anti-invasive effect of imiquimod over a 
range of concentrations in the two melanoma cell lines, a 
modified version of the standard transwell filter assay for 
invasion was performed. As shown in Fig. 2A∼C and 2E∼
G, the migratory activity and invasion potential of the two 
melanoma cell lines were significantly suppressed by 
increasing concentrations of imiquimod over 24 hours of 
incubation. Fig. 2D and H show the percentages of re-
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Fig. 4. Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) protein and mRNA in SK-MEL-2 and SK-MEL-24 cell 
lines following treatment with imiquimod. Expression of MT1-MMP proteins in SK-MEL-2 (A) and SK-MEL-24 (B) cell lines was 
dose-dependently decreased with increasing concentrations of imiquimod. Relative mRNA expression of MT1-MMP in SK-MEL-2 (C) 
and SK-MEL-24 (D) cell lines, following treatment with a range of imiquimod concentrations (5, 10, 30 μg/ml), compared to controls 
(0 μg/ml). Con A: concanavalin A. *p＜0.05 vs. control. 
lative cell counts after the invasion assay. The number of 
invading melanoma cells was significantly decreased by 
the increasing concentrations of imiquimod. Invading cells 
were 31.57% and 55.96% lower in SK-MEL-2 cells treated 
with 10 and 30 μg/ml imiquimod, respectively, as com-
pared to the non-treated SK-MEL-2 cells (Fig. 2D). Invasion 
of SK-MEL-24 cells was significantly decreased by 43.87% 
and 67.02% after treatment with 10 and 30 μg/ml imiqui-
mod, respectively, as compared with non-treated SK-MEL- 
24 cells (Fig. 2H).
Imiquimod induced changes in matrix metalloprote-
inase-2 and -9 expression in human melanoma cells
Gelatin zymography and real-time quantitative RT-PCR 
were performed to determine whether the function of imi-
quimod in control of melanoma invasiveness is dependent 
on MMP expression and activity. 
In gelatin zymography, only the inactive form of MMP-2 
was detected in the SK-MEL-2 cell line (Fig. 3A), while 
both the inactive and active forms of MMP-2 were ob-
served in the SK-MEL-24 cells (Fig. 3B). Expression of 
MMP-2 decreased following incubation with increasing 
concentrations of imiquimod in both cell lines (Fig. 3A, 
B). However, the expression of MMP-9 was different in 
the SK-MEL-2 and SK-MLE-24 cell lines. Inactive and 
active forms of MMP-9 were observed in SK-MEL-2 cell 
line (Fig. 3C), while only its inactive form was observed in 
SK-MEL-24 cells (Fig. 3D). SK-MEL-2 cells showed a 
concentration-dependent increase in MMP-9 expression 
following imiquimod incubation (Fig. 3C). However, ex-
pression of MMP-9 decreased with increasing imiquimod 
concentrations in SK-MEL-24 cell lines (Fig. 3D). 
In real-time quantitative RT-PCR investigations, expression 
of MMP-2 and -9 mRNA showed a pattern similar to the 
one observed with MMP-2 and -9 proteins in both cell 
lines. In SK-MEL-2 cells, MMP-2 mRNA showed a signi-
ficant concentration-dependent decrease following treat-
ment with imiquimod at all concentrations (p＜0.05; Fig. 
3E). In SK-MEL-24 cells, mRNA expression of MMP-2 also 
exhibited concentration-dependent decreases following 
imiquimod treatment. Significantly decreased expression 
of MMP-2 mRNA was detected in SK-MEL-24 cells fo-
llowing incubations with 10 and 30 μg/ml imiquimod, 
compared with untreated cells (p＜0.05; Fig. 3F). MMP-9 
mRNA expression in SK-MEL-2 cells tended to increase 
with increasing concentrations of imiquimod, but the 
relationship was not statistical significant (Fig. 3G). In 
SK-MEL-24 cells, significantly decreased mRNA expre-
ssion of MMP-9 was observed following 30 μg/ml imi-
quimod (p＜0.05; Fig. 3H).
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Fig. 5. Expression of tissue inhibitors of metalloproteinase (TIMP)-1 and -2 protein and mRNA in SK-MEL-2 and SK-MEL-24 cell lines 
following incubation with imiquimod. Expression of TIMP-1 protein was dose-dependently increased by imiquimod in SK-MEL-2 (A) 
and SK-MEL-24 cells (B). Expression of TIMP-2 protein was also dose-dependently elevated by imiquimod in SK-MEL-2 (C) and SK-MEL-24 
cells (D). Relative mRNA expression of TIMP-1 in SK-MEL-2 (E) and SK-MLE-24 (F) cells and TIMP-2 in SK-MEL-2 (G) and SK-MLE-24 
(H) cells, following treatment with a range of concentrations of imiquimod (5, 10, and 30 μg/ml), compared to controls (0 μg/ml). 
*p＜0.05 vs. control.
Expression of membrane type 1-matrix metalloprote-
inase decreased with imiquimod treatment in human 
melanoma cells
To investigate the changes in MT1-MMP protein expre-
ssion, western blot analysis was performed on the whole- 
cell protein extracts of melanoma cells treated with imi-
quimod (0∼30 μg/ml). Both inactive and active MT1- 
MMP proteins were detected in both melanoma cell lines. 
Expression of MT1-MMP proteins was found to be in-
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versely proportional to the concentration of imiquimod in 
both cell lines (Fig. 4A, B). 
A significant concentration-dependent decrease in MT1- 
MMP mRNA was observed in SK-MEL-2 cells following 
treatment with imiquimod at all concentrations (p＜0.05; 
Fig. 4C). In SK-MEL-24 cells, mRNA expression of MT1- 
MMP was decreased in a concentration-dependent mann-
er following imiquimod treatment, with a statistically 
significant decrease observed at 30 μg/ml (p＜0.05; Fig. 
4D).
Imiquimod-induced expression of tissue inhibitors of 
metalloproteinase-1 and -2 in human melanoma cells
Whole protein extracts obtained from conditioned media 
of two melanoma cell lines treated with 0 to 30 μg/ml of 
imiquimod were collected and concentrated. TIMP-1 and 
-2 proteins were detected in both melanoma cell lines 
following treatment with all concentrations of imiquimod. 
Expression of TIMP-1 protein showed a tendency to in-
crease with increasing imiquimod concentration in both 
cell lines (Fig. 5A, B). Elevated TIMP-2 protein expression 
was also observed in concentration-dependent patterns in 
both cell lines (Fig. 5C, D). 
In real-time quantitative RT-PCR investigations, changes in 
TIMP-1 and -2 mRNA levels showed a pattern similar to 
that observed with TIMP-1 and -2 protein levels in both 
cell lines. Additionally, mRNA expression of TIMP-1 in 
SK-MEL-2 cells tended to increase with increasing con-
centrations of imiquimod, but the imiquimod-induced 
changes did not reach statistical significance (Fig. 5E). In 
SK-MEL-24 cells, mRNA expression of TIMP-1 was ele-
vated with increasing imiquimod in a concentration- 
dependent manner, with statistically significant differences 
observed at 30 μg/ml of imiquimod (p＜0.05, compared 
to control cells; Fig. 5F). TIMP-2 mRNA expression tended 
to increase with the concentration of imiquimod in SK- 
MEL-2 cells, without reaching statistical significance (Fig. 
5G). Lastly, mRNA expression of TIMP-2 in SK-MEL-24 
cells was significantly increased in a concentration-depen-
dent manner following treatment with all concentrations 
of imiquimod (p＜0.05; Fig. 5H).
DISCUSSION
Previous studies investigating imiquimod focused mainly 
on its antitumor effects, elicited through the induction of 
profound cellular tumor-directed immune responses by 
inflammatory cells8,9 or through direct pro-apoptotic acti-
vity against tumor cells8,10,11. This study demonstrated that 
imiquimod suppresses the invasion of melanoma cells in a 
concentration-dependent manner.
Cancer invasion and metastasis occurs through degra-
dation of stromal connective tissue and the components of 
the basement membrane12,13. In order to invade and me-
tastasize, tumor cells adhere to the ECM and degrade it 
through the secretion and activation of multiple prote-
olytic enzymes, particularly MMPs14. Increased MMP ac-
tivity is related to tumor growth, invasion, and angio-
genesis15-17. TIMPs are specific inhibitors that regulate the 
local activities of MMPs18-20 and include TIMP-1, -2, -3, 
and -415,21,22. Melanoma cells show expression of MMP-1, 
-2, -9, -13, and MT1-MMP, as well as inhibitors TIMP-1, 
-2, and -36,23.
Among MMPs, MMP-2 and its inhibitor TIMP-2 have been 
found to control degradation of type IV collagen, which is 
the main component of the basement membrane. MMP-2 
is, therefore, an important enzyme known to degrade the 
surrounding ECM components during cancer invasion and 
metastasis24,25. A relationship between MMP-2 expression 
and prognosis of melanoma has been reported. An in-
crease in MMP-2 expression was found to correlate with 
hematogenous metastasis of melanoma23,26,27. In the curr-
ent study, imiquimod decreased the expression of MMP-2 
in a concentration-dependent manner in both melanoma 
cell lines studied. This observed effect may be associated 
with the imiquimod-mediated suppression of melanoma 
invasion and metastasis. 
MMP-9 enzyme has the ability to degrade type IV colla-
gen, plays a key role in the early stages of tumor invasion 
and metastasis, and is inhibited by TIMP-128. Imbalance in 
the production of MMP-9 and TIMP-1 is involved in the 
regulation of ECM degradation, thereby affecting tumor 
invasion and metastasis29. The exact role of MMP-9 in me-
lanoma progression is controversial. Expression of MMP-9 
in primary melanoma was observed in the horizontal 
growth phase, but not in the vertical growth phase23,30. On 
the other hand, expression of MMP-9 was observed in a 
melanoma cell line derived from advanced primary me-
lanoma, but not in a melanoma cell line derived from 
early primary melanoma31. Tumor cells from spontaneous 
lymph node and pulmonary metastases were found to 
express mostly MMP-9, whereas no MMP-9 expression 
was detected in cells from experimental metastases32. In 
our current study, expression of MMP-9 in the two mela-
noma cell lines studied was altered in the opposite di-
rections by the incubation with imiquimod. Expression of 
MMP-9 was increased in the SK-MEL-2 cell line, but 
decreased in the SK-MEL-24 cell line with increasing 
imiquimod concentrations. The observed difference in the 
effect may be related to the origin of the melanoma cell 
lines. The SK-MEL-2 cell line was derived from a skin 
metastasis of melanoma, while the SK-MEL-24 cell line 
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was derived from a lymph node metastasis of melanoma. 
Selected tumor cells in different environments may exhibit 
different properties, which influence their invasiveness 
and capacity to metastasize to different organs; therefore, 
metastases to various organs may occur by different 
mechanisms. These unique characteristics of each cell 
could be reflected in their response to imiquimod. Further 
studies are warranted to determine the biochemical factors 
involved in the control of MMP-9 expression in melanoma 
cell lines. Expression of TIMP-1 showed a concentration- 
dependent increase following imiquimod treatment in 
both cell lines. In this study, suppression of the invasi-
veness of the two melanoma cell lines was independent of 
changes in MMP-9 expression. Our findings, therefore, 
suggest that imiquimod-induced increases in TIMP-1 may 
play a more important role in the control of melanoma 
cell invasion than the changes in MMP-9.
MT1-MMP is a membrane-bound MMP that plays a dual 
role in degradation of ECM in the tumor invasion proc-
ess33,34. MT1-MMP can activate proMMP-2 and degrade a 
number of ECM components35-37, thereby promoting tu-
mor invasion and metastasis. In primary and metastatic 
melanoma, expression of MMP-2 and MT1-MMP enzymes 
was found to be increased. Melanoma cells co-expressing 
MMP-2 and MT1-MMP were often located at the front of 
the melanoma invasion process. Melanoma cells expre-
ssing MMP-2 also showed co-expression of MT1-MMP 
and TIMP-223,38. TIMP-2 serves to bridge the interaction 
between MMP-2 and MT1-MMP. At low TIMP-2 con-
centrations, proMMP-2 is activated by free MT1-MMP. At 
high intracellular TIMP-2 concentrations, most MT1-MMP 
forms complexes with TIMP-2, which function as recep-
tors for proMMP-2. The ternary complex of MT1-MMP/ 
TIMP-2/proMMP-2 interacts with the adjacent free-MT1- 
MMP altering proMMP-2 activation. Overall, this process 
partially decreases the activation of proMMP-239,40. In our 
current study, imiquimod treatment resulted in a concen-
tration-dependent decrease in MMP-2 and MT1-MMP le-
vels, while TIMP-2 levels were observed to increase with 
increasing concentrations of imiquimod. These changes 
may act synergistically to suppress the invasiveness of 
melanoma cells mediated through MMPs and TIMPs.
Over-expression of TIMP-1, -2, and -3 was observed du-
ring the progression of melanoma41. Over-expression of 
TIMP-1 and -2 reduces the experimental metastasis of 
melanoma42,43. TIMPs were also reported to exhibit apo-
ptosis-inducing properties44. In human melanoma cell li-
nes, expression of TIMP-1 and -2 was increased by imi-
quimod treatment in a dose-dependent manner. Increases 
in TIMP-1 and -2 levels can directly suppress the activity 
of MMPs in melanoma, thereby suppressing melanoma 
invasion and metastasis. 
In the future, anti-cancer treatments focused on regulating 
MMP and TIMP activity warrant further development for 
clinical use. The results of our current study suggest that 
imiquimod may be used to attenuate cancer progression 
by suppressing cancer invasion and metastasis. However, 
further investigations evaluating the anti-invasive and anti- 
metastatic effects of imiquimod, including in vivo studies 
in human patients and murine disease models, are nee-
ded. 
In conclusion, imiquimod induced a concentration-depen-
dent suppression of invasion in human malignant mela-
noma cell lines. Incubation with imiquimod also caused 
concentration-dependent alterations in the expression of 
MMPs and TIMPs. These results suggest that imiquimod 
may elicit an anti-invasive effect on human melanoma 
cells by regulating the balance of MMPs and TIMPs. 
ACKNOWLEDGMENT
This study was supported by a faculty research grant of 
Yonsei University College of Medicine for 2009 (6-2009- 
0089) and research grant from Stiefel in 2009.
REFERENCES
1. van Meurs T, van Doorn R, Kirtschig G. Recurrence of len-
tigo maligna after initial complete response to treatment 
with 5% imiquimod cream. Dermatol Surg 2007;33:623- 
626.
2. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo 
maligna (melanoma in situ) with the immune response 
modifier imiquimod. Arch Dermatol 2005;141:510-514.
3. Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, 
Mackinnis C, et al. Treatment of lentigo maligna with topical 
imiquimod. Br J Dermatol 2003;149 Suppl 66:66-70.
4. Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo 
maligna with imiquimod before staged excision. Dermatol 
Surg 2008;34:147-151.
5. Woodmansee CS, McCall MW. Recurrence of lentigo 
maligna and development of invasive melanoma after 
treatment of lentigo maligna with imiquimod. Dermatol Surg 
2009;35:1286-1289.
6. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. 
Matrix metalloproteinases in human melanoma. J Invest 
Dermatol 2000;115:337-344.
7. Hesling C, D'Incan M, Mansard S, Franck F, Corbin-Duval 
A, Chèvenet C, et al. In vivo and in situ modulation of the 
expression of genes involved in metastasis and angiogenesis 
in a patient treated with topical imiquimod for melanoma 
skin metastases. Br J Dermatol 2004;150:761-767.
8. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino 
K, et al. Small anti-viral compounds activate immune cells 
via the TLR7 MyD88-dependent signaling pathway. Nat 
JY Jung, et al
372 Ann Dermatol
Immunol 2002;3:196-200.
9. Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Rei-
fenberger J, et al. Tumor-selective induction of apoptosis and 
the small-molecule immune response modifier imiquimod. J 
Natl Cancer Inst 2003;95:1138-1149.
10. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Sch-
mook T, Sterry W. The use of Toll-like receptor-7 agonist in 
the treatment of basal cell carcinoma: an overview. Br J 
Dermatol 2003;149 Suppl 66:53-56.
11. Schön MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, 
Geilen CC, et al. Death receptor-independent apoptosis in 
malignant melanoma induced by the small-molecule imm-
une response modifier imiquimod. J Invest Dermatol 2004; 
122:1266-1276.
12. Felding-Habermann B. Integrin adhesion receptors in tumor 
metastasis. Clin Exp Metastasis 2003;20:203-213.
13. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of 
tumor cells with the basement membrane. Annu Rev Bio-
chem 1986;55:1037-1057.
14. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a 
tail of a frog that became a prince. Nat Rev Mol Cell Biol 
2002;3:207-214.
15. Sun J. Matrix metalloproteinases and tissue inhibitor of meta-
lloproteinases are essential for the inflammatory response in 
cancer cells. J Signal Transduct 2010;2010:985132.
16. Gokaslan ZL, Chintala SK, York JE, Boyapati V, Jasti S, 
Sawaya R, et al. Expression and role of matrix metallopro-
teinases MMP-2 and MMP-9 in human spinal column 
tumors. Clin Exp Metastasis 1998;16:721-728.
17. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: 
regulators of the tumor microenvironment. Cell 2010;141: 
52-67.
18. Visse R, Nagase H. Matrix metalloproteinases and tissue 
inhibitors of metalloproteinases: structure, function, and bio-
chemistry. Circ Res 2003;92:827-839.
19. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue 
inhibitors of metalloproteinases: structure, regulation and 
biological functions. Eur J Cell Biol 1997;74:111-122.
20. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of 
metalloproteinases: evolution, structure and function. Bioch-
im Biophys Acta 2000;1477:267-283.
21. Stetler-Stevenson WG, Seo DW. TIMP-2: an endogenous 
inhibitor of angiogenesis. Trends Mol Med 2005;11:97-103.
22. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular 
matrix 6: role of matrix metalloproteinases in tumor invasion 
and metastasis. FASEB J 1993;7:1434-1441.
23. Hofmann UB, Houben R, Bröcker EB, Becker JC. Role of 
matrix metalloproteinases in melanoma cell invasion. Bio-
chimie 2005;87:307-314.
24. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie 
S. Metastatic potential correlates with enzymatic degradation 
of basement membrane collagen. Nature 1980;284:67-68.
25. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, 
Goldberg GI. Mechanism of cell surface activation of 72- 
kDa type IV collagenase. Isolation of the activated form of 
the membrane metalloprotease. J Biol Chem 1995;270: 
5331-5338.
26. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hu-
janen T. Matrix metalloproteinase-2 (72 kD type IV co-
llagenase) expression occurs in the early stage of human 
melanocytic tumour progression and may have prognostic 
value. J Pathol 1996;180:283-289.
27. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hu-
janen T. Prognostic value of MMP-2 immunoreactive protein 
(72 kD type IV collagenase) in primary skin melanoma. J 
Pathol 1998;186:51-58.
28. Pyke C, Ralfkiaer E, Tryggvason K, Danø K. Messenger RNA 
for two type IV collagenases is located in stromal cells in 
human colon cancer. Am J Pathol 1993;142:359-365.
29. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of 
matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and 
their inhibitors (TIMP-1, TIMP-2) in common epithelial 
tumors of the ovary. Int J Oncol 2000;17:673-681.
30. van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters 
C. Expression of gelatinase B and the extracellular matrix 
metalloproteinase inducer EMMPRIN in benign and mali-
gnant pigment cell lesions of the skin. Am J Pathol 1997; 
151:665-670.
31. MacDougall JR, Bani MR, Lin Y, Rak J, Kerbel RS. The 92- 
kDa gelatinase B is expressed by advanced stage melanoma 
cells: suppression by somatic cell hybridization with early 
stage melanoma cells. Cancer Res 1995;55:4174-4181.
32. Hofmann UB, Eggert AA, Blass K, Bröcker EB, Becker JC. 
Expression of matrix metalloproteinases in the microen-
vironment of spontaneous and experimental melanoma 
metastases reflects the requirements for tumor formation. 
Cancer Res 2003;63:8221-8225.
33. d'Ortho MP, Will H, Atkinson S, Butler G, Messent A, 
Gavrilovic J, et al. Membrane-type matrix metalloproteinases 
1 and 2 exhibit broad-spectrum proteolytic capacities com-
parable to many matrix metalloproteinases. Eur J Biochem 
1997;250:751-757.
34. Deryugina EI, Soroceanu L, Strongin AY. Up-regulation of 
vascular endothelial growth factor by membrane-type 1 
matrix metalloproteinase stimulates human glioma xenograft 
growth and angiogenesis. Cancer Res 2002;62:580-588.
35. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ. Regulation 
of cell invasion and morphogenesis in a three-dimensional 
type I collagen matrix by membrane-type matrix metallopro-
teinases 1, 2, and 3. J Cell Biol 2000;149:1309-1323.
36. Iida J, Wilhelmson KL, Price MA, Wilson CM, Pei D, Furcht 
LT, et al. Membrane type-1 matrix metalloproteinase promo-
tes human melanoma invasion and growth. J Invest Der-
matol 2004;122:167-176.
37. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, Schade 
van Westrum S, et al. The TIMP2 membrane type 1 meta-
lloproteinase "receptor" regulates the concentration and effi-
cient activation of progelatinase A. A kinetic study. J Biol 
Chem 1998;273:871-880.
38. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter 
DJ, van Muijen GN. Expression and activation of matrix 
metalloproteinase-2 (MMP-2) and its co-localization with 
membrane-type 1 matrix metalloproteinase (MT1-MMP) co-
rrelate with melanoma progression. J Pathol 2000;191: 
Effect of Imiquimod in Melanoma Cell Invasion
Vol. 26, No. 3, 2014 373
245-256.
39. Stetler-Stevenson WG. The tumor microenvironment: regula-
tion by MMP-independent effects of tissue inhibitor of 
metalloproteinases-2. Cancer Metastasis Rev 2008;27:57-66.
40. Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N, et al. 
Homophilic complex formation of MT1-MMP facilitates pro-
MMP-2 activation on the cell surface and promotes tumor 
cell invasion. EMBO J 2001;20:4782-4793.
41. Henriet P, Blavier L, Declerck YA. Tissue inhibitors of 
metalloproteinases (TIMP) in invasion and proliferation. 
APMIS 1999;107:111-119.
42. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, 
DeClerck YA. Effect of tissue inhibitor of the matrix metallo-
proteinases-2 expression on the growth and spontaneous 
metastasis of a human melanoma cell line. Cancer Res 
1994;54:5467-5473.
43. Khokha R. Suppression of the tumorigenic and metastatic 
abilities of murine B16-F10 melanoma cells in vivo by the 
overexpression of the tissue inhibitor of the metallopro-
teinases-1. J Natl Cancer Inst 1994;86:299-304.
44. Finan KM, Hodge G, Reynolds AM, Hodge S, Holmes MD, 
Baker AH, et al. In vitro susceptibility to the pro-apoptotic 
effects of TIMP-3 gene delivery translates to greater in vivo 
efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer 
2006;53:273-284.
